Enasidenib (AG-221) in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase 1 dose-escalation and expansion study Meeting Abstract

   


Authors: Stein, E. M.; DiNardo, C. D.; Pollyea, D. A.; Fathi, A. T.; Roboz, G. J.; Altman, J. K.; Stone, R. M.; Flinn, I. W.; Kantarjian, H. M.; Collins, R.; Patel, M. R.; Stein, A.; Sekeres, M. A.; Swords, R. T.; Medeiros, B. C.; Knight, R. D.; Agresta, S.; de Botton, S.; Tallman, M. S.
Abstract Title: Enasidenib (AG-221) in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase 1 dose-escalation and expansion study
Meeting Title: 22nd Congress of the European Hematology Association (EHA)
Journal Title: Haematologica
Volume: 102
Issue: Suppl. 2
Meeting Dates: 2017 Jun 22-25
Meeting Location: Madrid, Spain
ISSN: 0390-6078
Publisher: Ferrata Storti Foundation  
Date Published: 2017-06-26
Start Page: 175
Language: English
ACCESSION: WOS:000404127001365
PROVIDER: wos
PMCID: PMC5492673
Notes: Meeting Abstract: S471 -- Source: Wos